Skip to main content
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc — Investor Relations & Filings

Ticker · XFOR ISIN · US0428731097 LEI · 549300R0UFVPXWP86U94 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2017-11-20 Director's Dealing
Country US United States of America
Listing US XFOR

About X4 Pharmaceuticals, Inc

https://www.x4pharma.com/

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2017-11-20 English
424B1
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus for an initial public offering (IPO) of common stock by Arsanis, Inc. It includes information about the offering size, price, underwriting, risk factors, business overview, management, financial data, and other disclosures typical of a registration statement or prospectus filed with the SEC. The document is not an annual report, earnings release, or any other financial report type. It is a capital markets document related to the issuance of new shares to the public. The appropriate classification for this type of document, which provides detailed information about a capital raising event, is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high given the clear identification as a prospectus for an IPO under SEC Rule 424(b)(1).
2017-11-17 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC. Form S-8 is used for registering securities to be offered under employee benefit plans, such as stock incentive plans and employee stock purchase plans. The document includes details about the plans, the number of shares to be registered, and indemnification provisions for directors and officers. It is not a financial report, earnings release, or management discussion, but a registration statement related to capital raising through employee stock plans. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the full registration statement, not just an announcement.
2017-11-16 English
Regulatory Filings 2017
Regulatory Filings
2017-11-16 English
FORM 3
Director's Dealing
2017-11-16 English
FORM 3 SUBMISSION
Director's Dealing
2017-11-15 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.